Combined Buprenorphine and Behavioral Treatment With and Without Contingent Reinforcement on Opioid and Cocaine Abstinence. - 22

This study has been completed.

Sponsored by:	National Institute on Drug Abuse (NIDA)
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000240

Purpose

The purpose of this study is to test combined buprenorphine and behavioral treatment with and without contingent reinforcement on opioid and cocaine abstinence.

Condition	Intervention	Phase
Cocaine-Related Disorders Opioid-Related Disorders	Drug: Buprenorphine	Phase II

Drug Information available for: Buprenorphine Buprenorphine hydrochloride 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- Cocaine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Open Label
Official Title:	Combined Buprenorphine and Behavioral Treatment Without Contingent Reinforcement

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Drug use
Retention
Weeks abstinent
Weeks continuous abstinence
Overall treatment outcome
Opioid dependence and psychiatric status

Estimated Enrollment:	0
Study Start Date:	April 1999

Eligibility

Ages Eligible for Study:	23 Years to 47 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000240

Locations

United States, Vermont
Treatment Research Center
Burlington, Vermont, United States, 05401

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Investigators

Principal Investigator:

Warren Bickel, Ph.D.

University of Vermont

More Information

Study ID Numbers:	NIDA-06969-22, R01-06969-22
Study First Received:	September 20, 1999
Last Updated:	August 16, 2005
ClinicalTrials.gov Identifier:	NCT00000240
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Cocaine-Related Disorders
Buprenorphine
Mental Disorders
Substance-Related Disorders

Disorders of Environmental Origin
Cocaine
Opioid-Related Disorders

Additional relevant MeSH terms:

Disease
Physiological Effects of Drugs
Narcotic Antagonists
Central Nervous System Depressants
Narcotics
Pharmacologic Actions
Pathologic Processes

Sensory System Agents
Therapeutic Uses
Analgesics
Peripheral Nervous System Agents
Central Nervous System Agents
Analgesics, Opioid

ClinicalTrials.gov processed this record on January 15, 2009